Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117170 | 0.85 | ACHE (0.46) | PIK3CAUSP30TBK1CKS1BSKP1 | |
| SCHEMBL20116978 | 0.82 | ACHE (0.47) | PIK3CAUSP30TBK1CKS1BSKP1 | |
| SCHEMBL20116315 | 0.81 | TBK1 (0.49) | PIK3CAUSP30TBK1CKS1BSKP1 | |
| SCHEMBL20676652 | 0.81 | USP30 (0.43) | PIK3CAUSP30TBK1ACHEGPR119 | |
| SCHEMBL20676316 | 0.80 | USP30 (0.42) | PIK3CAUSP30TBK1ACHEGPR119 | |
| SCHEMBL387529 | 0.79 | CKS1B (0.56) | PIK3CACKS1BSKP1SKP2ACHE | |
| SCHEMBL30818961 | 0.77 | CKS1B (0.53) | PIK3CACKS1BSKP1SKP2ACHE | |
| SCHEMBL391852 | 0.77 | GBA1 (0.57) | PIK3CACKS1BSKP1SKP2ACHE | |
| SCHEMBL3443191 | 0.76 | CKS1B (0.64) | PIK3CAUSP30LRRK2CKS1BSKP1 | |
| SCHEMBL20116528 | 0.75 | USP30 (0.43) | PIK3CAUSP30TBK1CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | PIK3CA 3734/4885USP30 3526/4885TBK1 3534/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | PIK3CA 3734/4885USP30 3526/4885TBK1 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.